nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—LRRK2—Crohn's disease	0.546	1	CbGaD
Bosutinib—Hepatitis toxic—Azathioprine—Crohn's disease	0.00514	0.0547	CcSEcCtD
Bosutinib—Hepatitis toxic—Mesalazine—Crohn's disease	0.00468	0.0498	CcSEcCtD
Bosutinib—Vandetanib—RIPK2—Crohn's disease	0.00364	0.85	CrCbGaD
Bosutinib—Myelosuppression—Mercaptopurine—Crohn's disease	0.00302	0.0321	CcSEcCtD
Bosutinib—Lipase increased—Mesalazine—Crohn's disease	0.00261	0.0278	CcSEcCtD
Bosutinib—Abdominal pain lower—Mesalazine—Crohn's disease	0.00242	0.0257	CcSEcCtD
Bosutinib—Pericardial effusion—Mesalazine—Crohn's disease	0.00187	0.0199	CcSEcCtD
Bosutinib—Hepatotoxicity—Mercaptopurine—Crohn's disease	0.00183	0.0195	CcSEcCtD
Bosutinib—Rash generalised—Mesalazine—Crohn's disease	0.00181	0.0192	CcSEcCtD
Bosutinib—Myelosuppression—Azathioprine—Crohn's disease	0.0018	0.0191	CcSEcCtD
Bosutinib—Pericarditis—Mesalazine—Crohn's disease	0.00178	0.0189	CcSEcCtD
Bosutinib—Liver injury—Mercaptopurine—Crohn's disease	0.00168	0.0179	CcSEcCtD
Bosutinib—Pancreatitis acute—Mesalazine—Crohn's disease	0.00166	0.0177	CcSEcCtD
Bosutinib—Prurigo—Mesalazine—Crohn's disease	0.00166	0.0177	CcSEcCtD
Bosutinib—Amylase increased—Mesalazine—Crohn's disease	0.00161	0.0172	CcSEcCtD
Bosutinib—Hepatotoxicity—Azathioprine—Crohn's disease	0.00109	0.0116	CcSEcCtD
Bosutinib—ERBB3—Methyldopa—Mesalazine—Crohn's disease	0.00104	0.376	CbGdCrCtD
Bosutinib—Pleural effusion—Mesalazine—Crohn's disease	0.001	0.0107	CcSEcCtD
Bosutinib—Liver injury—Azathioprine—Crohn's disease	0.001	0.0107	CcSEcCtD
Bosutinib—Hepatotoxicity—Mesalazine—Crohn's disease	0.000995	0.0106	CcSEcCtD
Bosutinib—Gamma-glutamyltransferase increased—Mesalazine—Crohn's disease	0.000934	0.00994	CcSEcCtD
Bosutinib—Acne—Mesalazine—Crohn's disease	0.000913	0.00972	CcSEcCtD
Bosutinib—Liver injury—Mesalazine—Crohn's disease	0.000913	0.00972	CcSEcCtD
Bosutinib—Pancreatitis acute—Prednisone—Crohn's disease	0.00088	0.00937	CcSEcCtD
Bosutinib—Pancytopenia—Mercaptopurine—Crohn's disease	0.000843	0.00898	CcSEcCtD
Bosutinib—Blood bilirubin increased—Mesalazine—Crohn's disease	0.000812	0.00864	CcSEcCtD
Bosutinib—Hepatobiliary disease—Mercaptopurine—Crohn's disease	0.000749	0.00797	CcSEcCtD
Bosutinib—Hepatic function abnormal—Azathioprine—Crohn's disease	0.0007	0.00746	CcSEcCtD
Bosutinib—Febrile neutropenia—Prednisone—Crohn's disease	0.000675	0.00719	CcSEcCtD
Bosutinib—Immune system disorder—Mercaptopurine—Crohn's disease	0.000642	0.00683	CcSEcCtD
Bosutinib—Malnutrition—Mercaptopurine—Crohn's disease	0.000619	0.00659	CcSEcCtD
Bosutinib—Renal failure acute—Mesalazine—Crohn's disease	0.000604	0.00643	CcSEcCtD
Bosutinib—STK25—digestive system—Crohn's disease	0.000589	0.00435	CbGeAlD
Bosutinib—BMPR2—smooth muscle tissue—Crohn's disease	0.000587	0.00434	CbGeAlD
Bosutinib—Renal impairment—Mesalazine—Crohn's disease	0.000586	0.00624	CcSEcCtD
Bosutinib—PLK2—lymphoid tissue—Crohn's disease	0.00058	0.00429	CbGeAlD
Bosutinib—BMPR2—skin of body—Crohn's disease	0.00058	0.00429	CbGeAlD
Bosutinib—MAP4K1—mammalian vulva—Crohn's disease	0.000578	0.00427	CbGeAlD
Bosutinib—PDGFRB—gall bladder—Crohn's disease	0.000578	0.00427	CbGeAlD
Bosutinib—BTK—mammalian vulva—Crohn's disease	0.000575	0.00425	CbGeAlD
Bosutinib—PLK2—digestive system—Crohn's disease	0.000573	0.00423	CbGeAlD
Bosutinib—Anaemia—Mercaptopurine—Crohn's disease	0.000572	0.00609	CcSEcCtD
Bosutinib—MAP2K1—epithelium—Crohn's disease	0.000567	0.00419	CbGeAlD
Bosutinib—MAP4K4—smooth muscle tissue—Crohn's disease	0.000565	0.00418	CbGeAlD
Bosutinib—EPHB2—Diflorasone—Prednisone—Crohn's disease	0.000559	0.203	CbGdCrCtD
Bosutinib—Gastrointestinal haemorrhage—Mesalazine—Crohn's disease	0.000558	0.00593	CcSEcCtD
Bosutinib—STK4—lymphoid tissue—Crohn's disease	0.000554	0.0041	CbGeAlD
Bosutinib—Leukopenia—Mercaptopurine—Crohn's disease	0.000554	0.00589	CcSEcCtD
Bosutinib—STK4—digestive system—Crohn's disease	0.000548	0.00405	CbGeAlD
Bosutinib—MAP2K1—smooth muscle tissue—Crohn's disease	0.000546	0.00404	CbGeAlD
Bosutinib—CSK—smooth muscle tissue—Crohn's disease	0.000542	0.00401	CbGeAlD
Bosutinib—MAP2K1—skin of body—Crohn's disease	0.000539	0.00398	CbGeAlD
Bosutinib—STK35—skin of body—Crohn's disease	0.000539	0.00398	CbGeAlD
Bosutinib—CSNK1A1—smooth muscle tissue—Crohn's disease	0.000539	0.00398	CbGeAlD
Bosutinib—Face oedema—Mesalazine—Crohn's disease	0.000538	0.00573	CcSEcCtD
Bosutinib—CSK—skin of body—Crohn's disease	0.000535	0.00396	CbGeAlD
Bosutinib—CSNK1A1—skin of body—Crohn's disease	0.000532	0.00393	CbGeAlD
Bosutinib—Arthralgia—Mercaptopurine—Crohn's disease	0.000527	0.00561	CcSEcCtD
Bosutinib—STK36—mammalian vulva—Crohn's disease	0.000524	0.00388	CbGeAlD
Bosutinib—EPHB3—mammalian vulva—Crohn's disease	0.000524	0.00388	CbGeAlD
Bosutinib—ALK—lymphoid tissue—Crohn's disease	0.000524	0.00387	CbGeAlD
Bosutinib—TYRO3—lymphoid tissue—Crohn's disease	0.000524	0.00387	CbGeAlD
Bosutinib—FER—lymphoid tissue—Crohn's disease	0.000524	0.00387	CbGeAlD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Mercaptopurine—Crohn's disease	0.000523	0.00557	CcSEcCtD
Bosutinib—Blood creatinine increased—Mesalazine—Crohn's disease	0.000522	0.00556	CcSEcCtD
Bosutinib—LYN—lymphoid tissue—Crohn's disease	0.000521	0.00385	CbGeAlD
Bosutinib—MERTK—mammalian vulva—Crohn's disease	0.000518	0.00383	CbGeAlD
Bosutinib—EPHA5—digestive system—Crohn's disease	0.000517	0.00383	CbGeAlD
Bosutinib—ALK—digestive system—Crohn's disease	0.000517	0.00383	CbGeAlD
Bosutinib—MAP4K1—lymphoid tissue—Crohn's disease	0.000513	0.00379	CbGeAlD
Bosutinib—BTK—lymphoid tissue—Crohn's disease	0.000511	0.00378	CbGeAlD
Bosutinib—Abdominal pain upper—Mesalazine—Crohn's disease	0.000509	0.00542	CcSEcCtD
Bosutinib—MAP4K4—mammalian vulva—Crohn's disease	0.000509	0.00376	CbGeAlD
Bosutinib—PTK2B—smooth muscle tissue—Crohn's disease	0.000508	0.00375	CbGeAlD
Bosutinib—Abdominal discomfort—Azathioprine—Crohn's disease	0.000507	0.0054	CcSEcCtD
Bosutinib—NUAK2—mammalian vulva—Crohn's disease	0.000505	0.00373	CbGeAlD
Bosutinib—BCR—mammalian vulva—Crohn's disease	0.000505	0.00373	CbGeAlD
Bosutinib—Oedema—Mercaptopurine—Crohn's disease	0.000505	0.00537	CcSEcCtD
Bosutinib—Pancytopenia—Azathioprine—Crohn's disease	0.000502	0.00535	CcSEcCtD
Bosutinib—Aspartate aminotransferase increased—Mesalazine—Crohn's disease	0.000502	0.00534	CcSEcCtD
Bosutinib—MAP3K12—mammalian vulva—Crohn's disease	0.000502	0.00371	CbGeAlD
Bosutinib—ERBB3—epithelium—Crohn's disease	0.0005	0.0037	CbGeAlD
Bosutinib—Nasopharyngitis—Mesalazine—Crohn's disease	0.000499	0.00531	CcSEcCtD
Bosutinib—MAP4K2—lymphoid tissue—Crohn's disease	0.000496	0.00367	CbGeAlD
Bosutinib—Thrombocytopenia—Mercaptopurine—Crohn's disease	0.000494	0.00526	CcSEcCtD
Bosutinib—Gastritis—Mesalazine—Crohn's disease	0.000493	0.00525	CcSEcCtD
Bosutinib—CSNK1E—skin of body—Crohn's disease	0.000493	0.00364	CbGeAlD
Bosutinib—Alanine aminotransferase increased—Mesalazine—Crohn's disease	0.000492	0.00523	CcSEcCtD
Bosutinib—Skin disorder—Mercaptopurine—Crohn's disease	0.00049	0.00522	CcSEcCtD
Bosutinib—CSK—mammalian vulva—Crohn's disease	0.000488	0.00361	CbGeAlD
Bosutinib—SIK1—skin of body—Crohn's disease	0.000485	0.00359	CbGeAlD
Bosutinib—CSNK1A1—mammalian vulva—Crohn's disease	0.000485	0.00359	CbGeAlD
Bosutinib—PTK2—epithelium—Crohn's disease	0.000485	0.00359	CbGeAlD
Bosutinib—ROCK1—lymphoid tissue—Crohn's disease	0.000483	0.00357	CbGeAlD
Bosutinib—Acne—Prednisone—Crohn's disease	0.000483	0.00514	CcSEcCtD
Bosutinib—CLK1—mammalian vulva—Crohn's disease	0.000482	0.00356	CbGeAlD
Bosutinib—HCK—mammalian vulva—Crohn's disease	0.000482	0.00356	CbGeAlD
Bosutinib—Influenza—Mesalazine—Crohn's disease	0.000482	0.00513	CcSEcCtD
Bosutinib—MAP2K2—smooth muscle tissue—Crohn's disease	0.000481	0.00355	CbGeAlD
Bosutinib—ROCK1—digestive system—Crohn's disease	0.000477	0.00353	CbGeAlD
Bosutinib—ERBB3—skin of body—Crohn's disease	0.000476	0.00352	CbGeAlD
Bosutinib—MAP2K2—skin of body—Crohn's disease	0.000474	0.00351	CbGeAlD
Bosutinib—Pneumonia—Azathioprine—Crohn's disease	0.000474	0.00505	CcSEcCtD
Bosutinib—MAP3K7—smooth muscle tissue—Crohn's disease	0.000473	0.00349	CbGeAlD
Bosutinib—Infestation—Azathioprine—Crohn's disease	0.000472	0.00502	CcSEcCtD
Bosutinib—Infestation NOS—Azathioprine—Crohn's disease	0.000472	0.00502	CcSEcCtD
Bosutinib—BMPR2—lymphoid tissue—Crohn's disease	0.000469	0.00347	CbGeAlD
Bosutinib—LRRK2—mammalian vulva—Crohn's disease	0.000469	0.00347	CbGeAlD
Bosutinib—EGFR—mammalian vulva—Crohn's disease	0.000467	0.00346	CbGeAlD
Bosutinib—PTK2—smooth muscle tissue—Crohn's disease	0.000467	0.00345	CbGeAlD
Bosutinib—RPS6KB1—epithelium—Crohn's disease	0.000467	0.00345	CbGeAlD
Bosutinib—BMPR2—digestive system—Crohn's disease	0.000464	0.00343	CbGeAlD
Bosutinib—Bronchitis—Mesalazine—Crohn's disease	0.000463	0.00493	CcSEcCtD
Bosutinib—Abdominal discomfort—Mesalazine—Crohn's disease	0.000462	0.00492	CcSEcCtD
Bosutinib—PTK2—skin of body—Crohn's disease	0.000461	0.00341	CbGeAlD
Bosutinib—MERTK—lymphoid tissue—Crohn's disease	0.00046	0.0034	CbGeAlD
Bosutinib—EPHB3—digestive system—Crohn's disease	0.00046	0.0034	CbGeAlD
Bosutinib—Musculoskeletal discomfort—Mercaptopurine—Crohn's disease	0.00046	0.0049	CcSEcCtD
Bosutinib—IRAK1—smooth muscle tissue—Crohn's disease	0.000458	0.00339	CbGeAlD
Bosutinib—Pancytopenia—Mesalazine—Crohn's disease	0.000458	0.00487	CcSEcCtD
Bosutinib—MAP4K4—lymphoid tissue—Crohn's disease	0.000452	0.00334	CbGeAlD
Bosutinib—Neutropenia—Mesalazine—Crohn's disease	0.000451	0.0048	CcSEcCtD
Bosutinib—RPS6KB1—smooth muscle tissue—Crohn's disease	0.00045	0.00332	CbGeAlD
Bosutinib—CSNK1E—mammalian vulva—Crohn's disease	0.00045	0.00332	CbGeAlD
Bosutinib—BCR—lymphoid tissue—Crohn's disease	0.000449	0.00332	CbGeAlD
Bosutinib—Upper respiratory tract infection—Mesalazine—Crohn's disease	0.000448	0.00477	CcSEcCtD
Bosutinib—MAP4K4—digestive system—Crohn's disease	0.000446	0.0033	CbGeAlD
Bosutinib—Hepatobiliary disease—Azathioprine—Crohn's disease	0.000446	0.00475	CcSEcCtD
Bosutinib—AXL—smooth muscle tissue—Crohn's disease	0.000445	0.00329	CbGeAlD
Bosutinib—SIK1—mammalian vulva—Crohn's disease	0.000443	0.00327	CbGeAlD
Bosutinib—IRAK4—mammalian vulva—Crohn's disease	0.000443	0.00327	CbGeAlD
Bosutinib—EPHB4—epithelium—Crohn's disease	0.000441	0.00326	CbGeAlD
Bosutinib—TLK1—lymph node—Crohn's disease	0.000441	0.00326	CbGeAlD
Bosutinib—Agranulocytosis—Azathioprine—Crohn's disease	0.00044	0.00469	CcSEcCtD
Bosutinib—AXL—skin of body—Crohn's disease	0.000439	0.00325	CbGeAlD
Bosutinib—Decreased appetite—Mercaptopurine—Crohn's disease	0.000439	0.00467	CcSEcCtD
Bosutinib—EPHA4—mammalian vulva—Crohn's disease	0.000438	0.00324	CbGeAlD
Bosutinib—MAP2K1—lymphoid tissue—Crohn's disease	0.000436	0.00323	CbGeAlD
Bosutinib—Gastrointestinal disorder—Mercaptopurine—Crohn's disease	0.000436	0.00464	CcSEcCtD
Bosutinib—PRKCQ—lymph node—Crohn's disease	0.000435	0.00321	CbGeAlD
Bosutinib—CSK—lymphoid tissue—Crohn's disease	0.000434	0.0032	CbGeAlD
Bosutinib—EPHA2—epithelium—Crohn's disease	0.000433	0.0032	CbGeAlD
Bosutinib—ULK3—mammalian vulva—Crohn's disease	0.000433	0.0032	CbGeAlD
Bosutinib—MAP2K2—mammalian vulva—Crohn's disease	0.000433	0.0032	CbGeAlD
Bosutinib—Pneumonia—Mesalazine—Crohn's disease	0.000432	0.0046	CcSEcCtD
Bosutinib—MAP2K1—digestive system—Crohn's disease	0.000431	0.00319	CbGeAlD
Bosutinib—CSNK1A1—lymphoid tissue—Crohn's disease	0.000431	0.00318	CbGeAlD
Bosutinib—Infestation NOS—Mesalazine—Crohn's disease	0.00043	0.00457	CcSEcCtD
Bosutinib—Infestation—Mesalazine—Crohn's disease	0.00043	0.00457	CcSEcCtD
Bosutinib—CSK—digestive system—Crohn's disease	0.000428	0.00317	CbGeAlD
Bosutinib—CLK1—lymphoid tissue—Crohn's disease	0.000428	0.00316	CbGeAlD
Bosutinib—HCK—lymphoid tissue—Crohn's disease	0.000428	0.00316	CbGeAlD
Bosutinib—MAP3K7—mammalian vulva—Crohn's disease	0.000426	0.00315	CbGeAlD
Bosutinib—CSNK1A1—digestive system—Crohn's disease	0.000425	0.00315	CbGeAlD
Bosutinib—EPHB4—smooth muscle tissue—Crohn's disease	0.000425	0.00314	CbGeAlD
Bosutinib—HCK—digestive system—Crohn's disease	0.000423	0.00312	CbGeAlD
Bosutinib—CLK1—digestive system—Crohn's disease	0.000423	0.00312	CbGeAlD
Bosutinib—Renal failure—Mesalazine—Crohn's disease	0.000422	0.0045	CcSEcCtD
Bosutinib—TBK1—mammalian vulva—Crohn's disease	0.000421	0.00311	CbGeAlD
Bosutinib—FYN—smooth muscle tissue—Crohn's disease	0.000417	0.00308	CbGeAlD
Bosutinib—CAMK2G—digestive system—Crohn's disease	0.000415	0.00307	CbGeAlD
Bosutinib—IRAK1—mammalian vulva—Crohn's disease	0.000412	0.00305	CbGeAlD
Bosutinib—FYN—skin of body—Crohn's disease	0.000411	0.00304	CbGeAlD
Bosutinib—BMX—lymph node—Crohn's disease	0.000408	0.00301	CbGeAlD
Bosutinib—CLK3—lymph node—Crohn's disease	0.000408	0.00301	CbGeAlD
Bosutinib—DSTYK—lymph node—Crohn's disease	0.000408	0.00301	CbGeAlD
Bosutinib—MAP4K5—smooth muscle tissue—Crohn's disease	0.000407	0.00301	CbGeAlD
Bosutinib—Hepatobiliary disease—Mesalazine—Crohn's disease	0.000406	0.00433	CcSEcCtD
Bosutinib—PTK2B—lymphoid tissue—Crohn's disease	0.000406	0.003	CbGeAlD
Bosutinib—RPS6KB1—mammalian vulva—Crohn's disease	0.000405	0.00299	CbGeAlD
Bosutinib—BLK—lymph node—Crohn's disease	0.000403	0.00298	CbGeAlD
Bosutinib—FGR—mammalian vulva—Crohn's disease	0.000402	0.00297	CbGeAlD
Bosutinib—LCK—mammalian vulva—Crohn's disease	0.000402	0.00297	CbGeAlD
Bosutinib—MAP3K3—skin of body—Crohn's disease	0.000402	0.00297	CbGeAlD
Bosutinib—Agranulocytosis—Mesalazine—Crohn's disease	0.000401	0.00427	CcSEcCtD
Bosutinib—PTK2B—digestive system—Crohn's disease	0.000401	0.00296	CbGeAlD
Bosutinib—AXL—mammalian vulva—Crohn's disease	0.000401	0.00296	CbGeAlD
Bosutinib—Erythema multiforme—Azathioprine—Crohn's disease	0.0004	0.00426	CcSEcCtD
Bosutinib—Body temperature increased—Mercaptopurine—Crohn's disease	0.000399	0.00425	CcSEcCtD
Bosutinib—CASK—lymph node—Crohn's disease	0.000399	0.00295	CbGeAlD
Bosutinib—PHKG1—lymph node—Crohn's disease	0.000399	0.00295	CbGeAlD
Bosutinib—CSNK1E—digestive system—Crohn's disease	0.000394	0.00291	CbGeAlD
Bosutinib—EIF2AK1—lymph node—Crohn's disease	0.000394	0.00291	CbGeAlD
Bosutinib—SIK1—lymphoid tissue—Crohn's disease	0.000393	0.0029	CbGeAlD
Bosutinib—IRAK4—lymphoid tissue—Crohn's disease	0.000393	0.0029	CbGeAlD
Bosutinib—TXK—lymph node—Crohn's disease	0.000386	0.00285	CbGeAlD
Bosutinib—Fluid retention—Prednisone—Crohn's disease	0.000386	0.00411	CcSEcCtD
Bosutinib—Hepatitis—Mesalazine—Crohn's disease	0.000386	0.00411	CcSEcCtD
Bosutinib—SLK—mammalian vulva—Crohn's disease	0.000386	0.00285	CbGeAlD
Bosutinib—ERBB3—lymphoid tissue—Crohn's disease	0.000385	0.00285	CbGeAlD
Bosutinib—MAP2K2—lymphoid tissue—Crohn's disease	0.000384	0.00284	CbGeAlD
Bosutinib—EPHB4—mammalian vulva—Crohn's disease	0.000383	0.00283	CbGeAlD
Bosutinib—Immune system disorder—Azathioprine—Crohn's disease	0.000382	0.00407	CcSEcCtD
Bosutinib—FES—lymph node—Crohn's disease	0.000382	0.00282	CbGeAlD
Bosutinib—VRK2—lymph node—Crohn's disease	0.000382	0.00282	CbGeAlD
Bosutinib—Mediastinal disorder—Azathioprine—Crohn's disease	0.000382	0.00406	CcSEcCtD
Bosutinib—MAP3K2—lymphoid tissue—Crohn's disease	0.000381	0.00282	CbGeAlD
Bosutinib—Urinary tract disorder—Mesalazine—Crohn's disease	0.000381	0.00405	CcSEcCtD
Bosutinib—ERBB3—digestive system—Crohn's disease	0.00038	0.00281	CbGeAlD
Bosutinib—Oedema peripheral—Mesalazine—Crohn's disease	0.00038	0.00404	CcSEcCtD
Bosutinib—ULK3—digestive system—Crohn's disease	0.000379	0.00281	CbGeAlD
Bosutinib—MAP2K2—digestive system—Crohn's disease	0.000379	0.00281	CbGeAlD
Bosutinib—Connective tissue disorder—Mesalazine—Crohn's disease	0.000379	0.00403	CcSEcCtD
Bosutinib—Urethral disorder—Mesalazine—Crohn's disease	0.000378	0.00402	CcSEcCtD
Bosutinib—YES1—smooth muscle tissue—Crohn's disease	0.000376	0.00278	CbGeAlD
Bosutinib—EPHA2—mammalian vulva—Crohn's disease	0.000376	0.00278	CbGeAlD
Bosutinib—SRC—epithelium—Crohn's disease	0.000375	0.00277	CbGeAlD
Bosutinib—FYN—mammalian vulva—Crohn's disease	0.000375	0.00277	CbGeAlD
Bosutinib—TNIK—lymph node—Crohn's disease	0.000375	0.00277	CbGeAlD
Bosutinib—SYK—lymph node—Crohn's disease	0.000375	0.00277	CbGeAlD
Bosutinib—PTK2—lymphoid tissue—Crohn's disease	0.000374	0.00276	CbGeAlD
Bosutinib—TBK1—lymphoid tissue—Crohn's disease	0.000374	0.00276	CbGeAlD
Bosutinib—CDK2—lymph node—Crohn's disease	0.000371	0.00274	CbGeAlD
Bosutinib—TBK1—digestive system—Crohn's disease	0.000369	0.00273	CbGeAlD
Bosutinib—PTK2—digestive system—Crohn's disease	0.000369	0.00273	CbGeAlD
Bosutinib—STK26—lymph node—Crohn's disease	0.000368	0.00272	CbGeAlD
Bosutinib—MAP3K3—mammalian vulva—Crohn's disease	0.000366	0.00271	CbGeAlD
Bosutinib—MAP4K5—mammalian vulva—Crohn's disease	0.000366	0.00271	CbGeAlD
Bosutinib—Erythema multiforme—Mesalazine—Crohn's disease	0.000365	0.00388	CcSEcCtD
Bosutinib—SRC—smooth muscle tissue—Crohn's disease	0.000362	0.00267	CbGeAlD
Bosutinib—Tinnitus—Mesalazine—Crohn's disease	0.00036	0.00383	CcSEcCtD
Bosutinib—RPS6KB1—lymphoid tissue—Crohn's disease	0.000359	0.00266	CbGeAlD
Bosutinib—Cardiac disorder—Mesalazine—Crohn's disease	0.000358	0.00381	CcSEcCtD
Bosutinib—FGR—lymphoid tissue—Crohn's disease	0.000357	0.00264	CbGeAlD
Bosutinib—SRC—skin of body—Crohn's disease	0.000357	0.00264	CbGeAlD
Bosutinib—AXL—lymphoid tissue—Crohn's disease	0.000356	0.00263	CbGeAlD
Bosutinib—CHEK2—lymph node—Crohn's disease	0.000355	0.00263	CbGeAlD
Bosutinib—RPS6KB1—digestive system—Crohn's disease	0.000355	0.00262	CbGeAlD
Bosutinib—FGR—digestive system—Crohn's disease	0.000353	0.00261	CbGeAlD
Bosutinib—WEE1—lymph node—Crohn's disease	0.000352	0.0026	CbGeAlD
Bosutinib—DMPK—lymph node—Crohn's disease	0.000352	0.0026	CbGeAlD
Bosutinib—Immune system disorder—Mesalazine—Crohn's disease	0.000348	0.00371	CcSEcCtD
Bosutinib—Mediastinal disorder—Mesalazine—Crohn's disease	0.000348	0.0037	CcSEcCtD
Bosutinib—Diarrhoea—Mercaptopurine—Crohn's disease	0.000345	0.00368	CcSEcCtD
Bosutinib—Ill-defined disorder—Azathioprine—Crohn's disease	0.000342	0.00364	CcSEcCtD
Bosutinib—Anaemia—Azathioprine—Crohn's disease	0.000341	0.00363	CcSEcCtD
Bosutinib—YES1—mammalian vulva—Crohn's disease	0.000338	0.0025	CbGeAlD
Bosutinib—STK25—lymph node—Crohn's disease	0.000336	0.00249	CbGeAlD
Bosutinib—EPHB4—digestive system—Crohn's disease	0.000336	0.00248	CbGeAlD
Bosutinib—STK10—mammalian vulva—Crohn's disease	0.000335	0.00248	CbGeAlD
Bosutinib—TAOK3—mammalian vulva—Crohn's disease	0.000334	0.00247	CbGeAlD
Bosutinib—EPHA3—lymph node—Crohn's disease	0.000334	0.00247	CbGeAlD
Bosutinib—EPHA2—lymphoid tissue—Crohn's disease	0.000334	0.00247	CbGeAlD
Bosutinib—FYN—lymphoid tissue—Crohn's disease	0.000333	0.00246	CbGeAlD
Bosutinib—Malaise—Azathioprine—Crohn's disease	0.000332	0.00354	CcSEcCtD
Bosutinib—Vandetanib—ALB—Crohn's disease	0.00033	0.0771	CrCbGaD
Bosutinib—Leukopenia—Azathioprine—Crohn's disease	0.00033	0.00351	CcSEcCtD
Bosutinib—EPHA2—digestive system—Crohn's disease	0.000329	0.00244	CbGeAlD
Bosutinib—FYN—digestive system—Crohn's disease	0.000329	0.00243	CbGeAlD
Bosutinib—Dysgeusia—Mesalazine—Crohn's disease	0.000329	0.0035	CcSEcCtD
Bosutinib—PLK2—lymph node—Crohn's disease	0.000327	0.00242	CbGeAlD
Bosutinib—MAP4K5—lymphoid tissue—Crohn's disease	0.000325	0.00241	CbGeAlD
Bosutinib—SIK3—lymph node—Crohn's disease	0.000325	0.0024	CbGeAlD
Bosutinib—Back pain—Mesalazine—Crohn's disease	0.000325	0.00346	CcSEcCtD
Bosutinib—CSF1R—smooth muscle tissue—Crohn's disease	0.000325	0.0024	CbGeAlD
Bosutinib—Vomiting—Mercaptopurine—Crohn's disease	0.000321	0.00342	CcSEcCtD
Bosutinib—CSF1R—skin of body—Crohn's disease	0.00032	0.00237	CbGeAlD
Bosutinib—Rash—Mercaptopurine—Crohn's disease	0.000318	0.00339	CcSEcCtD
Bosutinib—Dermatitis—Mercaptopurine—Crohn's disease	0.000318	0.00339	CcSEcCtD
Bosutinib—PKMYT1—Danazol—Prednisone—Crohn's disease	0.000317	0.115	CbGdCrCtD
Bosutinib—Gefitinib—ALB—Crohn's disease	0.000314	0.0732	CrCbGaD
Bosutinib—Arthralgia—Azathioprine—Crohn's disease	0.000314	0.00334	CcSEcCtD
Bosutinib—Myalgia—Azathioprine—Crohn's disease	0.000314	0.00334	CcSEcCtD
Bosutinib—STK4—lymph node—Crohn's disease	0.000313	0.00231	CbGeAlD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—Crohn's disease	0.000312	0.00332	CcSEcCtD
Bosutinib—Ill-defined disorder—Mesalazine—Crohn's disease	0.000312	0.00332	CcSEcCtD
Bosutinib—Anaemia—Mesalazine—Crohn's disease	0.00031	0.0033	CcSEcCtD
Bosutinib—Discomfort—Azathioprine—Crohn's disease	0.00031	0.0033	CcSEcCtD
Bosutinib—CAMK1D—lymph node—Crohn's disease	0.000309	0.00228	CbGeAlD
Bosutinib—STK24—lymph node—Crohn's disease	0.000305	0.00226	CbGeAlD
Bosutinib—Malaise—Mesalazine—Crohn's disease	0.000303	0.00322	CcSEcCtD
Bosutinib—CSNK1E—Danazol—Prednisone—Crohn's disease	0.000303	0.11	CbGdCrCtD
Bosutinib—Leukopenia—Mesalazine—Crohn's disease	0.000301	0.0032	CcSEcCtD
Bosutinib—YES1—lymphoid tissue—Crohn's disease	0.0003	0.00222	CbGeAlD
Bosutinib—Nausea—Mercaptopurine—Crohn's disease	0.0003	0.00319	CcSEcCtD
Bosutinib—MAP2K5—mammalian vulva—Crohn's disease	0.000299	0.00221	CbGeAlD
Bosutinib—Infection—Azathioprine—Crohn's disease	0.000299	0.00318	CcSEcCtD
Bosutinib—PDGFRB—epithelium—Crohn's disease	0.000299	0.00221	CbGeAlD
Bosutinib—STK10—lymphoid tissue—Crohn's disease	0.000298	0.0022	CbGeAlD
Bosutinib—YES1—digestive system—Crohn's disease	0.000297	0.00219	CbGeAlD
Bosutinib—TAOK3—lymphoid tissue—Crohn's disease	0.000297	0.00219	CbGeAlD
Bosutinib—FER—lymph node—Crohn's disease	0.000296	0.00219	CbGeAlD
Bosutinib—ALK—lymph node—Crohn's disease	0.000296	0.00219	CbGeAlD
Bosutinib—Gastrointestinal haemorrhage—Prednisone—Crohn's disease	0.000295	0.00314	CcSEcCtD
Bosutinib—Thrombocytopenia—Azathioprine—Crohn's disease	0.000295	0.00314	CcSEcCtD
Bosutinib—STK10—digestive system—Crohn's disease	0.000294	0.00217	CbGeAlD
Bosutinib—TAOK3—digestive system—Crohn's disease	0.000293	0.00217	CbGeAlD
Bosutinib—Cough—Mesalazine—Crohn's disease	0.000293	0.00312	CcSEcCtD
Bosutinib—CSF1R—mammalian vulva—Crohn's disease	0.000292	0.00216	CbGeAlD
Bosutinib—Skin disorder—Azathioprine—Crohn's disease	0.000292	0.00311	CcSEcCtD
Bosutinib—MAP4K1—lymph node—Crohn's disease	0.00029	0.00214	CbGeAlD
Bosutinib—SRC—lymphoid tissue—Crohn's disease	0.000289	0.00214	CbGeAlD
Bosutinib—BTK—lymph node—Crohn's disease	0.000288	0.00213	CbGeAlD
Bosutinib—PDGFRB—smooth muscle tissue—Crohn's disease	0.000288	0.00213	CbGeAlD
Bosutinib—Arthralgia—Mesalazine—Crohn's disease	0.000286	0.00304	CcSEcCtD
Bosutinib—Myalgia—Mesalazine—Crohn's disease	0.000286	0.00304	CcSEcCtD
Bosutinib—Chest pain—Mesalazine—Crohn's disease	0.000286	0.00304	CcSEcCtD
Bosutinib—SRC—digestive system—Crohn's disease	0.000286	0.00211	CbGeAlD
Bosutinib—Face oedema—Prednisone—Crohn's disease	0.000285	0.00303	CcSEcCtD
Bosutinib—PDGFRB—skin of body—Crohn's disease	0.000284	0.0021	CbGeAlD
Bosutinib—TNK2—lymph node—Crohn's disease	0.000284	0.0021	CbGeAlD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Mesalazine—Crohn's disease	0.000284	0.00302	CcSEcCtD
Bosutinib—Discomfort—Mesalazine—Crohn's disease	0.000282	0.00301	CcSEcCtD
Bosutinib—MAP4K2—lymph node—Crohn's disease	0.00028	0.00207	CbGeAlD
Bosutinib—STK3—lymph node—Crohn's disease	0.000276	0.00204	CbGeAlD
Bosutinib—Musculoskeletal discomfort—Azathioprine—Crohn's disease	0.000274	0.00292	CcSEcCtD
Bosutinib—Oedema—Mesalazine—Crohn's disease	0.000274	0.00292	CcSEcCtD
Bosutinib—Anaphylactic shock—Mesalazine—Crohn's disease	0.000274	0.00292	CcSEcCtD
Bosutinib—Infection—Mesalazine—Crohn's disease	0.000272	0.0029	CcSEcCtD
Bosutinib—Nervous system disorder—Mesalazine—Crohn's disease	0.000269	0.00286	CcSEcCtD
Bosutinib—Thrombocytopenia—Mesalazine—Crohn's disease	0.000268	0.00286	CcSEcCtD
Bosutinib—Skin disorder—Mesalazine—Crohn's disease	0.000266	0.00283	CcSEcCtD
Bosutinib—BMPR2—lymph node—Crohn's disease	0.000265	0.00196	CbGeAlD
Bosutinib—STK36—lymph node—Crohn's disease	0.000263	0.00194	CbGeAlD
Bosutinib—EPHB3—lymph node—Crohn's disease	0.000263	0.00194	CbGeAlD
Bosutinib—Alanine aminotransferase increased—Prednisone—Crohn's disease	0.00026	0.00277	CcSEcCtD
Bosutinib—MERTK—lymph node—Crohn's disease	0.00026	0.00192	CbGeAlD
Bosutinib—Gastrointestinal disorder—Azathioprine—Crohn's disease	0.00026	0.00276	CcSEcCtD
Bosutinib—CSF1R—lymphoid tissue—Crohn's disease	0.00026	0.00192	CbGeAlD
Bosutinib—PDGFRB—mammalian vulva—Crohn's disease	0.000259	0.00192	CbGeAlD
Bosutinib—ABL1—smooth muscle tissue—Crohn's disease	0.000257	0.0019	CbGeAlD
Bosutinib—CSF1R—digestive system—Crohn's disease	0.000256	0.0019	CbGeAlD
Bosutinib—MAP4K4—lymph node—Crohn's disease	0.000255	0.00188	CbGeAlD
Bosutinib—ABL1—skin of body—Crohn's disease	0.000253	0.00187	CbGeAlD
Bosutinib—BCR—lymph node—Crohn's disease	0.000253	0.00187	CbGeAlD
Bosutinib—NUAK2—lymph node—Crohn's disease	0.000253	0.00187	CbGeAlD
Bosutinib—MAP3K12—lymph node—Crohn's disease	0.000251	0.00186	CbGeAlD
Bosutinib—Musculoskeletal discomfort—Mesalazine—Crohn's disease	0.00025	0.00266	CcSEcCtD
Bosutinib—Feeling abnormal—Azathioprine—Crohn's disease	0.000248	0.00264	CcSEcCtD
Bosutinib—MAP2K1—lymph node—Crohn's disease	0.000246	0.00182	CbGeAlD
Bosutinib—STK35—lymph node—Crohn's disease	0.000246	0.00182	CbGeAlD
Bosutinib—Gastrointestinal pain—Azathioprine—Crohn's disease	0.000246	0.00262	CcSEcCtD
Bosutinib—CSK—lymph node—Crohn's disease	0.000245	0.00181	CbGeAlD
Bosutinib—Dyspnoea—Mesalazine—Crohn's disease	0.000244	0.0026	CcSEcCtD
Bosutinib—CSNK1A1—lymph node—Crohn's disease	0.000243	0.0018	CbGeAlD
Bosutinib—HCK—lymph node—Crohn's disease	0.000241	0.00178	CbGeAlD
Bosutinib—CLK1—lymph node—Crohn's disease	0.000241	0.00178	CbGeAlD
Bosutinib—ABL2—lymph node—Crohn's disease	0.00024	0.00177	CbGeAlD
Bosutinib—Neutropenia—Prednisone—Crohn's disease	0.000238	0.00254	CcSEcCtD
Bosutinib—Decreased appetite—Mesalazine—Crohn's disease	0.000238	0.00254	CcSEcCtD
Bosutinib—Body temperature increased—Azathioprine—Crohn's disease	0.000238	0.00253	CcSEcCtD
Bosutinib—Abdominal pain—Azathioprine—Crohn's disease	0.000238	0.00253	CcSEcCtD
Bosutinib—CAMK2G—lymph node—Crohn's disease	0.000237	0.00175	CbGeAlD
Bosutinib—BMP2K—lymph node—Crohn's disease	0.000237	0.00175	CbGeAlD
Bosutinib—Gastrointestinal disorder—Mesalazine—Crohn's disease	0.000237	0.00252	CcSEcCtD
Bosutinib—Fatigue—Mesalazine—Crohn's disease	0.000236	0.00251	CcSEcCtD
Bosutinib—LRRK2—lymph node—Crohn's disease	0.000235	0.00174	CbGeAlD
Bosutinib—Pain—Mesalazine—Crohn's disease	0.000234	0.00249	CcSEcCtD
Bosutinib—EGFR—lymph node—Crohn's disease	0.000234	0.00173	CbGeAlD
Bosutinib—ABL1—mammalian vulva—Crohn's disease	0.000231	0.00171	CbGeAlD
Bosutinib—PDGFRB—lymphoid tissue—Crohn's disease	0.00023	0.0017	CbGeAlD
Bosutinib—PTK2B—lymph node—Crohn's disease	0.000229	0.00169	CbGeAlD
Bosutinib—PDGFRB—digestive system—Crohn's disease	0.000227	0.00168	CbGeAlD
Bosutinib—Feeling abnormal—Mesalazine—Crohn's disease	0.000226	0.0024	CcSEcCtD
Bosutinib—CSNK1E—lymph node—Crohn's disease	0.000225	0.00166	CbGeAlD
Bosutinib—Gastrointestinal pain—Mesalazine—Crohn's disease	0.000224	0.00239	CcSEcCtD
Bosutinib—SIK1—lymph node—Crohn's disease	0.000222	0.00164	CbGeAlD
Bosutinib—IRAK4—lymph node—Crohn's disease	0.000222	0.00164	CbGeAlD
Bosutinib—EPHA4—lymph node—Crohn's disease	0.000219	0.00162	CbGeAlD
Bosutinib—Urticaria—Mesalazine—Crohn's disease	0.000218	0.00232	CcSEcCtD
Bosutinib—ERBB3—lymph node—Crohn's disease	0.000217	0.00161	CbGeAlD
Bosutinib—ULK3—lymph node—Crohn's disease	0.000217	0.0016	CbGeAlD
Bosutinib—MAP2K2—lymph node—Crohn's disease	0.000217	0.0016	CbGeAlD
Bosutinib—Abdominal pain—Mesalazine—Crohn's disease	0.000217	0.00231	CcSEcCtD
Bosutinib—Body temperature increased—Mesalazine—Crohn's disease	0.000217	0.00231	CcSEcCtD
Bosutinib—MAP3K2—lymph node—Crohn's disease	0.000215	0.00159	CbGeAlD
Bosutinib—MAP3K7—lymph node—Crohn's disease	0.000213	0.00158	CbGeAlD
Bosutinib—PTK2—lymph node—Crohn's disease	0.000211	0.00156	CbGeAlD
Bosutinib—TBK1—lymph node—Crohn's disease	0.000211	0.00156	CbGeAlD
Bosutinib—IRAK1—lymph node—Crohn's disease	0.000207	0.00153	CbGeAlD
Bosutinib—Diarrhoea—Azathioprine—Crohn's disease	0.000206	0.00219	CcSEcCtD
Bosutinib—ABL1—lymphoid tissue—Crohn's disease	0.000205	0.00152	CbGeAlD
Bosutinib—RPS6KB1—lymph node—Crohn's disease	0.000203	0.0015	CbGeAlD
Bosutinib—ABL1—digestive system—Crohn's disease	0.000203	0.0015	CbGeAlD
Bosutinib—LCK—lymph node—Crohn's disease	0.000202	0.00149	CbGeAlD
Bosutinib—FGR—lymph node—Crohn's disease	0.000202	0.00149	CbGeAlD
Bosutinib—AXL—lymph node—Crohn's disease	0.000201	0.00148	CbGeAlD
Bosutinib—Connective tissue disorder—Prednisone—Crohn's disease	0.000201	0.00213	CcSEcCtD
Bosutinib—Dizziness—Azathioprine—Crohn's disease	0.000199	0.00212	CcSEcCtD
Bosutinib—Asthenia—Mesalazine—Crohn's disease	0.000197	0.00209	CcSEcCtD
Bosutinib—Pruritus—Mesalazine—Crohn's disease	0.000194	0.00206	CcSEcCtD
Bosutinib—CSNK1E—Betamethasone—Prednisone—Crohn's disease	0.000193	0.0701	CbGdCrCtD
Bosutinib—CSNK1E—Dexamethasone—Prednisone—Crohn's disease	0.000193	0.0701	CbGdCrCtD
Bosutinib—SLK—lymph node—Crohn's disease	0.000193	0.00143	CbGeAlD
Bosutinib—EPHB4—lymph node—Crohn's disease	0.000192	0.00142	CbGeAlD
Bosutinib—Vomiting—Azathioprine—Crohn's disease	0.000191	0.00204	CcSEcCtD
Bosutinib—Rash—Azathioprine—Crohn's disease	0.00019	0.00202	CcSEcCtD
Bosutinib—Dermatitis—Azathioprine—Crohn's disease	0.00019	0.00202	CcSEcCtD
Bosutinib—Headache—Azathioprine—Crohn's disease	0.000188	0.00201	CcSEcCtD
Bosutinib—EPHA2—lymph node—Crohn's disease	0.000188	0.00139	CbGeAlD
Bosutinib—FYN—lymph node—Crohn's disease	0.000188	0.00139	CbGeAlD
Bosutinib—Diarrhoea—Mesalazine—Crohn's disease	0.000187	0.002	CcSEcCtD
Bosutinib—Immune system disorder—Prednisone—Crohn's disease	0.000184	0.00196	CcSEcCtD
Bosutinib—MAP4K5—lymph node—Crohn's disease	0.000184	0.00136	CbGeAlD
Bosutinib—MAP3K3—lymph node—Crohn's disease	0.000184	0.00136	CbGeAlD
Bosutinib—Dizziness—Mesalazine—Crohn's disease	0.000181	0.00193	CcSEcCtD
Bosutinib—Nausea—Azathioprine—Crohn's disease	0.000179	0.0019	CcSEcCtD
Bosutinib—Malnutrition—Prednisone—Crohn's disease	0.000178	0.00189	CcSEcCtD
Bosutinib—Vomiting—Mesalazine—Crohn's disease	0.000174	0.00185	CcSEcCtD
Bosutinib—Rash—Mesalazine—Crohn's disease	0.000173	0.00184	CcSEcCtD
Bosutinib—Dermatitis—Mesalazine—Crohn's disease	0.000173	0.00184	CcSEcCtD
Bosutinib—Headache—Mesalazine—Crohn's disease	0.000172	0.00183	CcSEcCtD
Bosutinib—YES1—lymph node—Crohn's disease	0.00017	0.00125	CbGeAlD
Bosutinib—STK10—lymph node—Crohn's disease	0.000168	0.00124	CbGeAlD
Bosutinib—TAOK3—lymph node—Crohn's disease	0.000167	0.00124	CbGeAlD
Bosutinib—Ill-defined disorder—Prednisone—Crohn's disease	0.000165	0.00175	CcSEcCtD
Bosutinib—Anaemia—Prednisone—Crohn's disease	0.000164	0.00175	CcSEcCtD
Bosutinib—SRC—lymph node—Crohn's disease	0.000163	0.00121	CbGeAlD
Bosutinib—Nausea—Mesalazine—Crohn's disease	0.000163	0.00173	CcSEcCtD
Bosutinib—Malaise—Prednisone—Crohn's disease	0.00016	0.00171	CcSEcCtD
Bosutinib—CHEK2—Danazol—Prednisone—Crohn's disease	0.000155	0.0562	CbGdCrCtD
Bosutinib—Myalgia—Prednisone—Crohn's disease	0.000151	0.00161	CcSEcCtD
Bosutinib—Arthralgia—Prednisone—Crohn's disease	0.000151	0.00161	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—Crohn's disease	0.00015	0.0016	CcSEcCtD
Bosutinib—MAP2K5—lymph node—Crohn's disease	0.00015	0.00111	CbGeAlD
Bosutinib—Discomfort—Prednisone—Crohn's disease	0.000149	0.00159	CcSEcCtD
Bosutinib—CSF1R—lymph node—Crohn's disease	0.000146	0.00108	CbGeAlD
Bosutinib—Anaphylactic shock—Prednisone—Crohn's disease	0.000145	0.00154	CcSEcCtD
Bosutinib—Oedema—Prednisone—Crohn's disease	0.000145	0.00154	CcSEcCtD
Bosutinib—Infection—Prednisone—Crohn's disease	0.000144	0.00153	CcSEcCtD
Bosutinib—Nervous system disorder—Prednisone—Crohn's disease	0.000142	0.00151	CcSEcCtD
Bosutinib—Skin disorder—Prednisone—Crohn's disease	0.000141	0.0015	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Prednisone—Crohn's disease	0.000132	0.00141	CcSEcCtD
Bosutinib—PDGFRB—lymph node—Crohn's disease	0.00013	0.00096	CbGeAlD
Bosutinib—Decreased appetite—Prednisone—Crohn's disease	0.000126	0.00134	CcSEcCtD
Bosutinib—Fatigue—Prednisone—Crohn's disease	0.000125	0.00133	CcSEcCtD
Bosutinib—Feeling abnormal—Prednisone—Crohn's disease	0.000119	0.00127	CcSEcCtD
Bosutinib—Gastrointestinal pain—Prednisone—Crohn's disease	0.000119	0.00126	CcSEcCtD
Bosutinib—ABL1—lymph node—Crohn's disease	0.000116	0.000856	CbGeAlD
Bosutinib—Urticaria—Prednisone—Crohn's disease	0.000115	0.00123	CcSEcCtD
Bosutinib—Abdominal pain—Prednisone—Crohn's disease	0.000115	0.00122	CcSEcCtD
Bosutinib—Body temperature increased—Prednisone—Crohn's disease	0.000115	0.00122	CcSEcCtD
Bosutinib—Asthenia—Prednisone—Crohn's disease	0.000104	0.00111	CcSEcCtD
Bosutinib—Pruritus—Prednisone—Crohn's disease	0.000103	0.00109	CcSEcCtD
Bosutinib—Diarrhoea—Prednisone—Crohn's disease	9.92e-05	0.00106	CcSEcCtD
Bosutinib—Dizziness—Prednisone—Crohn's disease	9.59e-05	0.00102	CcSEcCtD
Bosutinib—Vomiting—Prednisone—Crohn's disease	9.22e-05	0.000981	CcSEcCtD
Bosutinib—Rash—Prednisone—Crohn's disease	9.14e-05	0.000973	CcSEcCtD
Bosutinib—Dermatitis—Prednisone—Crohn's disease	9.13e-05	0.000972	CcSEcCtD
Bosutinib—Headache—Prednisone—Crohn's disease	9.08e-05	0.000967	CcSEcCtD
Bosutinib—CYP3A4—digestive system—Crohn's disease	8.9e-05	0.000658	CbGeAlD
Bosutinib—Nausea—Prednisone—Crohn's disease	8.61e-05	0.000917	CcSEcCtD
Bosutinib—ABCB1—epithelium—Crohn's disease	8.28e-05	0.000612	CbGeAlD
Bosutinib—ABCB1—mammalian vulva—Crohn's disease	7.18e-05	0.000531	CbGeAlD
Bosutinib—ABCB1—lymphoid tissue—Crohn's disease	6.38e-05	0.000472	CbGeAlD
Bosutinib—ABCB1—digestive system—Crohn's disease	6.3e-05	0.000466	CbGeAlD
Bosutinib—ABCB1—lymph node—Crohn's disease	3.6e-05	0.000266	CbGeAlD
Bosutinib—MAP2K2—Disease—TYK2—Crohn's disease	2.49e-06	1.14e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—CXCL8—Crohn's disease	2.48e-06	1.14e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—IL2RA—Crohn's disease	2.48e-06	1.14e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—IFNG—Crohn's disease	2.47e-06	1.13e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—JAK2—Crohn's disease	2.46e-06	1.13e-05	CbGpPWpGaD
Bosutinib—PTK2—Immune System—STAT3—Crohn's disease	2.45e-06	1.13e-05	CbGpPWpGaD
Bosutinib—LYN—Developmental Biology—IL6—Crohn's disease	2.45e-06	1.12e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IL3—Crohn's disease	2.45e-06	1.12e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—JAK2—Crohn's disease	2.45e-06	1.12e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—CD4—Crohn's disease	2.44e-06	1.12e-05	CbGpPWpGaD
Bosutinib—ABL1—Developmental Biology—IL6—Crohn's disease	2.44e-06	1.12e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—TYK2—Crohn's disease	2.43e-06	1.12e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—JAK2—Crohn's disease	2.43e-06	1.11e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—SOCS1—Crohn's disease	2.43e-06	1.11e-05	CbGpPWpGaD
Bosutinib—FES—Signaling Pathways—IL6—Crohn's disease	2.42e-06	1.11e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—JAK2—Crohn's disease	2.42e-06	1.11e-05	CbGpPWpGaD
Bosutinib—YES1—Immune System—STAT3—Crohn's disease	2.42e-06	1.11e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—IL2RA—Crohn's disease	2.42e-06	1.11e-05	CbGpPWpGaD
Bosutinib—IRAK4—Immune System—IL6—Crohn's disease	2.42e-06	1.11e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—IFNG—Crohn's disease	2.41e-06	1.11e-05	CbGpPWpGaD
Bosutinib—FYN—Developmental Biology—IL6—Crohn's disease	2.41e-06	1.11e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—MTMR3—Crohn's disease	2.41e-06	1.11e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—JAK2—Crohn's disease	2.41e-06	1.1e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—CXCL8—Crohn's disease	2.41e-06	1.1e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—IFNG—Crohn's disease	2.4e-06	1.1e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—TLR4—Crohn's disease	2.4e-06	1.1e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Developmental Biology—IL6—Crohn's disease	2.4e-06	1.1e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—TYK2—Crohn's disease	2.4e-06	1.1e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—CXCL8—Crohn's disease	2.39e-06	1.1e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—CD4—Crohn's disease	2.38e-06	1.09e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—IFNG—Crohn's disease	2.38e-06	1.09e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—JAK2—Crohn's disease	2.38e-06	1.09e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—RASGRP1—Crohn's disease	2.37e-06	1.09e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—IL2RA—Crohn's disease	2.37e-06	1.09e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—IFNG—Crohn's disease	2.36e-06	1.08e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—TYK2—Crohn's disease	2.34e-06	1.07e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—STAT3—Crohn's disease	2.34e-06	1.07e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Disease—IL6—Crohn's disease	2.33e-06	1.07e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—CD4—Crohn's disease	2.33e-06	1.07e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—TYK2—Crohn's disease	2.33e-06	1.07e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—IL2RA—Crohn's disease	2.33e-06	1.07e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—CD4—Crohn's disease	2.32e-06	1.06e-05	CbGpPWpGaD
Bosutinib—HCK—Immune System—IL6—Crohn's disease	2.32e-06	1.06e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—JAK2—Crohn's disease	2.32e-06	1.06e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—IL2RA—Crohn's disease	2.32e-06	1.06e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—ICAM1—Crohn's disease	2.3e-06	1.06e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—CXCL8—Crohn's disease	2.3e-06	1.06e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—CXCL8—Crohn's disease	2.3e-06	1.06e-05	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—STAT3—Crohn's disease	2.3e-06	1.05e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—CD4—Crohn's disease	2.29e-06	1.05e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—JAK2—Crohn's disease	2.29e-06	1.05e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—CD4—Crohn's disease	2.28e-06	1.05e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling by GPCR—IL6—Crohn's disease	2.27e-06	1.04e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—TYK2—Crohn's disease	2.27e-06	1.04e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Innate Immune System—IL6—Crohn's disease	2.27e-06	1.04e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—IL1B—Crohn's disease	2.25e-06	1.03e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—CD4—Crohn's disease	2.25e-06	1.03e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—PTGS2—Crohn's disease	2.24e-06	1.03e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—JAK2—Crohn's disease	2.24e-06	1.03e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—TYK2—Crohn's disease	2.23e-06	1.03e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—JAK2—Crohn's disease	2.22e-06	1.02e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—CXCL8—Crohn's disease	2.22e-06	1.02e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Innate Immune System—IL6—Crohn's disease	2.21e-06	1.01e-05	CbGpPWpGaD
Bosutinib—SRC—Developmental Biology—TNF—Crohn's disease	2.2e-06	1.01e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—IL1B—Crohn's disease	2.2e-06	1.01e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—CD4—Crohn's disease	2.2e-06	1.01e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—TYK2—Crohn's disease	2.19e-06	1.01e-05	CbGpPWpGaD
Bosutinib—ERBB4—Immune System—IL6—Crohn's disease	2.18e-06	1e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—PTGS2—Crohn's disease	2.18e-06	1e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—SMAD3—Crohn's disease	2.17e-06	9.97e-06	CbGpPWpGaD
Bosutinib—LYN—Innate Immune System—IL6—Crohn's disease	2.16e-06	9.93e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—JAK2—Crohn's disease	2.16e-06	9.92e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—STAT3—Crohn's disease	2.16e-06	9.92e-06	CbGpPWpGaD
Bosutinib—ABL1—Innate Immune System—IL6—Crohn's disease	2.15e-06	9.88e-06	CbGpPWpGaD
Bosutinib—PTK2B—Immune System—IL6—Crohn's disease	2.15e-06	9.88e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—IL1B—Crohn's disease	2.15e-06	9.88e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—SOCS1—Crohn's disease	2.15e-06	9.85e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—IL1B—Crohn's disease	2.14e-06	9.83e-06	CbGpPWpGaD
Bosutinib—HCK—Disease—IL6—Crohn's disease	2.14e-06	9.82e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—JAK2—Crohn's disease	2.13e-06	9.78e-06	CbGpPWpGaD
Bosutinib—FYN—Innate Immune System—IL6—Crohn's disease	2.13e-06	9.78e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—TYK2—Crohn's disease	2.12e-06	9.72e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—IL1B—Crohn's disease	2.12e-06	9.72e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Innate Immune System—IL6—Crohn's disease	2.12e-06	9.72e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—CD4—Crohn's disease	2.12e-06	9.72e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—TYK2—Crohn's disease	2.11e-06	9.69e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—IL1B—Crohn's disease	2.11e-06	9.67e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—CD4—Crohn's disease	2.11e-06	9.67e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—PTGS2—Crohn's disease	2.1e-06	9.65e-06	CbGpPWpGaD
Bosutinib—BLK—Immune System—IL6—Crohn's disease	2.1e-06	9.64e-06	CbGpPWpGaD
Bosutinib—FGR—Immune System—IL6—Crohn's disease	2.09e-06	9.61e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—SMAD3—Crohn's disease	2.09e-06	9.61e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—PTGS2—Crohn's disease	2.09e-06	9.6e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—JAK2—Crohn's disease	2.09e-06	9.59e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—CXCL8—Crohn's disease	2.09e-06	9.58e-06	CbGpPWpGaD
Bosutinib—EGFR—Developmental Biology—IL6—Crohn's disease	2.08e-06	9.56e-06	CbGpPWpGaD
Bosutinib—SYK—Signaling Pathways—IL6—Crohn's disease	2.06e-06	9.45e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—IFNG—Crohn's disease	2.05e-06	9.42e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—TYK2—Crohn's disease	2.02e-06	9.29e-06	CbGpPWpGaD
Bosutinib—CSNK1A1—Signaling Pathways—IL6—Crohn's disease	2.02e-06	9.28e-06	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling Pathways—IL6—Crohn's disease	2.02e-06	9.28e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—JAK2—Crohn's disease	2.02e-06	9.28e-06	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—STAT3—Crohn's disease	2.02e-06	9.28e-06	CbGpPWpGaD
Bosutinib—ERBB4—Disease—IL6—Crohn's disease	2.02e-06	9.25e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—JAK2—Crohn's disease	2.02e-06	9.25e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IL2RA—Crohn's disease	2.01e-06	9.23e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—TYK2—Crohn's disease	2e-06	9.16e-06	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—STAT3—Crohn's disease	1.99e-06	9.14e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—CD4—Crohn's disease	1.98e-06	9.1e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—IFNG—Crohn's disease	1.98e-06	9.08e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—CXCL8—Crohn's disease	1.97e-06	9.05e-06	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—IL6—Crohn's disease	1.95e-06	8.96e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—TYK2—Crohn's disease	1.95e-06	8.95e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—CXCL8—Crohn's disease	1.95e-06	8.93e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IL2RA—Crohn's disease	1.94e-06	8.89e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—JAK2—Crohn's disease	1.93e-06	8.86e-06	CbGpPWpGaD
Bosutinib—ERBB3—Immune System—IL6—Crohn's disease	1.93e-06	8.84e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—STAT3—Crohn's disease	1.92e-06	8.81e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—CD4—Crohn's disease	1.91e-06	8.77e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—JAK2—Crohn's disease	1.9e-06	8.74e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—STAT3—Crohn's disease	1.89e-06	8.67e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—FADS1—Crohn's disease	1.88e-06	8.62e-06	CbGpPWpGaD
Bosutinib—ABCB1—Transmembrane transport of small molecules—ALB—Crohn's disease	1.87e-06	8.6e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—TYK2—Crohn's disease	1.87e-06	8.58e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—JAK2—Crohn's disease	1.86e-06	8.54e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—SMAD3—Crohn's disease	1.85e-06	8.5e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—STAT3—Crohn's disease	1.85e-06	8.49e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—STAT3—Crohn's disease	1.85e-06	8.49e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—CXCL8—Crohn's disease	1.85e-06	8.47e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—STAT3—Crohn's disease	1.84e-06	8.46e-06	CbGpPWpGaD
Bosutinib—EGFR—Innate Immune System—IL6—Crohn's disease	1.84e-06	8.45e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—IL1B—Crohn's disease	1.83e-06	8.4e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—CD4—Crohn's disease	1.83e-06	8.4e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—PTGS2—Crohn's disease	1.82e-06	8.34e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—STAT3—Crohn's disease	1.8e-06	8.28e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—STAT3—Crohn's disease	1.8e-06	8.24e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—JAK2—Crohn's disease	1.78e-06	8.19e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—STAT3—Crohn's disease	1.78e-06	8.18e-06	CbGpPWpGaD
Bosutinib—SRC—Developmental Biology—IL6—Crohn's disease	1.78e-06	8.16e-06	CbGpPWpGaD
Bosutinib—ERBB3—Disease—IL6—Crohn's disease	1.78e-06	8.16e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—STAT3—Crohn's disease	1.78e-06	8.15e-06	CbGpPWpGaD
Bosutinib—LCK—Innate Immune System—IL6—Crohn's disease	1.77e-06	8.14e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—STAT3—Crohn's disease	1.77e-06	8.11e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—IL1B—Crohn's disease	1.76e-06	8.1e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—CD4—Crohn's disease	1.76e-06	8.09e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GPX4—Crohn's disease	1.76e-06	8.07e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—IFNG—Crohn's disease	1.75e-06	8.03e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—PTGS2—Crohn's disease	1.75e-06	8.03e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—TYK2—Crohn's disease	1.74e-06	8e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—STAT3—Crohn's disease	1.74e-06	8e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—CXCL8—Crohn's disease	1.74e-06	7.97e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—TYK2—Crohn's disease	1.73e-06	7.92e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IL2RA—Crohn's disease	1.72e-06	7.87e-06	CbGpPWpGaD
Bosutinib—PTK2—Immune System—IL6—Crohn's disease	1.71e-06	7.86e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—TYK2—Crohn's disease	1.7e-06	7.81e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—STAT3—Crohn's disease	1.7e-06	7.81e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GCKR—Crohn's disease	1.7e-06	7.8e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—CD4—Crohn's disease	1.69e-06	7.76e-06	CbGpPWpGaD
Bosutinib—YES1—Immune System—IL6—Crohn's disease	1.69e-06	7.76e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—TYK2—Crohn's disease	1.67e-06	7.65e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—JAK2—Crohn's disease	1.66e-06	7.63e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—JAK2—Crohn's disease	1.65e-06	7.56e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—TYK2—Crohn's disease	1.64e-06	7.53e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—STAT3—Crohn's disease	1.64e-06	7.53e-06	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—IL6—Crohn's disease	1.63e-06	7.5e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—TYK2—Crohn's disease	1.63e-06	7.49e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—STAT3—Crohn's disease	1.63e-06	7.49e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—JAK2—Crohn's disease	1.62e-06	7.45e-06	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—IL6—Crohn's disease	1.6e-06	7.36e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—JAK2—Crohn's disease	1.59e-06	7.29e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—STAT3—Crohn's disease	1.59e-06	7.28e-06	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—IL6—Crohn's disease	1.57e-06	7.21e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—JAK2—Crohn's disease	1.57e-06	7.18e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—STAT3—Crohn's disease	1.56e-06	7.18e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—IL1B—Crohn's disease	1.56e-06	7.17e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—CD4—Crohn's disease	1.56e-06	7.16e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—JAK2—Crohn's disease	1.56e-06	7.14e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—PTGS2—Crohn's disease	1.55e-06	7.11e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—STAT3—Crohn's disease	1.54e-06	7.04e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—CXCL8—Crohn's disease	1.52e-06	6.97e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—IL6—Crohn's disease	1.51e-06	6.93e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—STAT3—Crohn's disease	1.48e-06	6.81e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—CXCL8—Crohn's disease	1.48e-06	6.8e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—STAT3—Crohn's disease	1.48e-06	6.79e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—CXCL8—Crohn's disease	1.45e-06	6.66e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—IL6—Crohn's disease	1.44e-06	6.63e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—CXCL8—Crohn's disease	1.43e-06	6.55e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—CXCL8—Crohn's disease	1.42e-06	6.52e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TYK2—Crohn's disease	1.42e-06	6.5e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—STAT3—Crohn's disease	1.42e-06	6.5e-06	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—IL6—Crohn's disease	1.41e-06	6.48e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—STAT3—Crohn's disease	1.4e-06	6.41e-06	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—IL6—Crohn's disease	1.39e-06	6.39e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TYK2—Crohn's disease	1.37e-06	6.27e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—STAT3—Crohn's disease	1.37e-06	6.27e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—JAK2—Crohn's disease	1.35e-06	6.2e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—IL6—Crohn's disease	1.35e-06	6.2e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—IL6—Crohn's disease	1.34e-06	6.15e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—IL6—Crohn's disease	1.32e-06	6.05e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—STAT3—Crohn's disease	1.31e-06	6.01e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—JAK2—Crohn's disease	1.3e-06	5.98e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—IL6—Crohn's disease	1.29e-06	5.93e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—IL6—Crohn's disease	1.29e-06	5.93e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—IL6—Crohn's disease	1.29e-06	5.91e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—IL6—Crohn's disease	1.26e-06	5.78e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—IL6—Crohn's disease	1.25e-06	5.76e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—IL6—Crohn's disease	1.25e-06	5.71e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—IL6—Crohn's disease	1.24e-06	5.69e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—IL6—Crohn's disease	1.23e-06	5.66e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CXCL8—Crohn's disease	1.23e-06	5.66e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—STAT3—Crohn's disease	1.22e-06	5.6e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—IL6—Crohn's disease	1.22e-06	5.59e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TYK2—Crohn's disease	1.21e-06	5.55e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—STAT3—Crohn's disease	1.21e-06	5.55e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—STAT3—Crohn's disease	1.19e-06	5.47e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CXCL8—Crohn's disease	1.19e-06	5.46e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—IL6—Crohn's disease	1.19e-06	5.45e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—IL6—Crohn's disease	1.17e-06	5.38e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—STAT3—Crohn's disease	1.17e-06	5.35e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—JAK2—Crohn's disease	1.15e-06	5.29e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—STAT3—Crohn's disease	1.15e-06	5.27e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—IL6—Crohn's disease	1.15e-06	5.26e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—STAT3—Crohn's disease	1.14e-06	5.24e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—IL6—Crohn's disease	1.14e-06	5.23e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—IL6—Crohn's disease	1.11e-06	5.08e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—IL6—Crohn's disease	1.09e-06	5.01e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—IL6—Crohn's disease	1.07e-06	4.92e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CXCL8—Crohn's disease	1.05e-06	4.83e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—IL6—Crohn's disease	1.04e-06	4.76e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—IL6—Crohn's disease	1.03e-06	4.74e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—STAT3—Crohn's disease	9.92e-07	4.55e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—IL6—Crohn's disease	9.9e-07	4.54e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—IL6—Crohn's disease	9.76e-07	4.48e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—STAT3—Crohn's disease	9.56e-07	4.39e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—IL6—Crohn's disease	9.54e-07	4.38e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—IL6—Crohn's disease	9.15e-07	4.2e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—ALB—Crohn's disease	8.78e-07	4.03e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—IL6—Crohn's disease	8.53e-07	3.91e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—STAT3—Crohn's disease	8.47e-07	3.88e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—IL6—Crohn's disease	8.45e-07	3.87e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—IL6—Crohn's disease	8.32e-07	3.82e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—IL6—Crohn's disease	8.15e-07	3.74e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—IL6—Crohn's disease	8.02e-07	3.68e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—IL6—Crohn's disease	7.98e-07	3.66e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PTGS2—Crohn's disease	7.68e-07	3.52e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IL6—Crohn's disease	6.93e-07	3.18e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IL6—Crohn's disease	6.68e-07	3.06e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IL6—Crohn's disease	5.91e-07	2.71e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ALB—Crohn's disease	5.41e-07	2.48e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PTGS2—Crohn's disease	4.73e-07	2.17e-06	CbGpPWpGaD
